Such findings highlighted the fact that 3rd-generation mesothelin-redirected CAR-Ts could also be choices of therapeutic value against ovarian cancer in preclinical settings; however, clinical studies must be conducted to directly assess the safety profile and tumoricidal efficacy of 2nd-generation and 3rd-generation mesothelin-redirected CAR-Ts in patients with mesothelin-positive ovarian cancer (149). This evidence concerns the gene MSLN and ovarian cancer.